Volv Global CEO Christopher Rudolf speaks at the DREAMS Neuromuscular Disease AI Webinar
Volv Global CEO Christopher Rudolf will speak at the DREAMS Neuromuscular Disease AI Webinar
Volv Global accelerates and de-risks clinical development strategies much earlier in the pharma development lifecycle, improving planning robustness and efficiency through better understanding of patients cohorts and diseases.
Machine learning research on real-world data: cohort analysis, biomarker discovery and evidence for trial design for better clinical strategies much earlier in the development lifecycle.
Understand disease and disease progression to find the right patients at the right point in the patient journey. Identify patient clusters to support trial site selection.
Elucidate disease heterogeneity and identify novel endpoints to signpost new biomarkers to optimise protocol design.
Use advance machine learning techniques to overcome issues of unstructured data, data sparsity and bias in data sources.
Clinical development in the face of complexity
Variability in phenotypic expression, progression and comorbidities complicates patient stratification and endpoint selection.
Rare diseases or subgroups have small patient populations and may lack sufficient data for robust insights.
Records may over-represent certain populations or healthcare systems, limiting generalisability.
Lack of longitudinal and complete datasets that capture the full trajectory of disease evolution makes it difficult to model disease progression.
Many critical insights are buried in free-text notes, requiring advanced natural language processing (NLP) to extract.
Limited understanding of disease biology hinders biomarker identification and endpoint selection for clinical trials.
Supporting Clinical Development
Growing the real-world evidence on a disease, and a clearer view of how many people it affects.
Studying the early biomarker patterns that precede a condition, sometimes years before conventional signs appear.
Modelling how disease progresses across diagnosed populations, using real-world evidence.
Sizing the diagnosed population not yet on treatment, and showing where the gap to care opens.
Leading AI/ML methodology to support Clinical Development
Our machine learning methodology is a robust resource to optimise trial design and patient recruitment by leveraging its AI/ML-driven analysis of extensive electronic health records, claims data, and other real-world evidence.
By detecting subtle biomarkers, phenotypes and other clinical features which characterise patients, sponsors can streamline enrollment and target the most relevant participants.
Additionally, its predictive modelling helps refine protocols and endpoints based on anticipated disease progression, ensuring sponsors gather higher-quality data and reduce trial timelines.
Shaping the future today
Volv Global CEO Christopher Rudolf will speak at the DREAMS Neuromuscular Disease AI Webinar
Volv Global at the 25th Annual NEALS Meeting, presenting new research on early identification of ALS using advanced M...
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
Results for the model flagging early ARDS risk in pneumonia will be presented at ERS Congress 2026.
Volv Global at ERS Congress 2026, presenting new research in collaboration with CSL Behring: Can We Catch ARDS Before...
Volv Global applied machine learning to 24M UK primary care records, surfacing ~1,200 undiagnosed GEP-NET patients, 5...
GEP-NETs are among the most diagnostically elusive tumours in oncology. This case study shows how machine learning ap...
Machine learning applied to 3,549 confirmed Pompe disease patients – the largest machine learning study of the diseas...
New research demonstrates that machine learning can map clinician-defined endpoints to real-world claims data in Pomp...
Explore Volv Global’s ISPOR 2026 research with Sanofi on Pompe disease, based on use of machine learning-driven endpo...
In Inflammatory Bowel Disease (IBD), steroids are considered a routine treatment, but repeated steroid exposure is a ...
AI-driven insights & RWD in Rare Disease: Accelerate AATD Diagnosis and identify undiagnosed AATD patients earlie...